Aethlon Medical Discloses New HIV/AIDS Treatment Data

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today disclosed new data resulting from its recent "first-in-human" application of the Aethlon Hemopurifier(R) to treat Human Immunodeficiency Virus (HIV), the disease that causes Acquired Immune Deficiency...

Cardiome Discloses Chairman And CEO's Involuntary Share Sale

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 28 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today disclosed that its Chairman and Chief Executive Officer, Bob Rieder, was recently subject to involuntary margin sales of 45,000 common shares from his direct holding of ...

Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant

Thermage Schedules Release Date and Conference Call Pro Forma Combined Third Quarter 2008 Revenue Growth of 8% HAYWARD, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM ) today provided preliminary results for the third quarter ended September 30, 2008 for...

American Scientific Resources, Inc. Discloses Reviewed Financials

Company Q1 2008 reviewed financials available on Pinksheets.com WESTON, Fla., June 23 /PRNewswire-FirstCall/ -- American Scientific Resources, Inc. ( http://www.americansci.com/ ) (Pink Sheets: ASFX) is pleased to announce that its reviewed Q1 2008 financials are now available on http://w...

Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need

HAE:TSX MONTREAL, April 10 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the results of a preclin...

Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission

KALAMAZOO, Mich., Oct. 12 /PRNewswire-FirstCall/ -- Stryker Corporation (NYSE: SYK ) disclosed today that the United States Securities and Exchange Commission has made an informal inquiry of the Company regarding possible violations of the Foreign Corrupt Practices Act in connection with the ...

Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side

WASHINGTON, Oct. 9 /PRNewswire-USNewswire/ -- Actor Joe Pantoliano reveals a personal history of depression and his belief that his mother struggled with untreated bipolar disorder, in a guest blog entry http://www.nami.org/blog published today by the National Alliance on Mental Illness (NAM...

Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009

...fferences between the U.S. GAAP and non-GAAP financial measures are reconciled in an attached schedule. In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating Par's underlying business performance. Managemen...

Lilly Announces Continued Commitment to Transparency with Faculty Registry

...ty appearing in the registry either advised Lilly or conducted medical lectures designed for health care professionals and patient education. The site discloses each professional's name, location, description of the services provided and the compensation paid, among other details. "This registry is con...

Boston Scientific Announces Results for Second Quarter Ended June 30, 2009

...AAP Financial Measures To supplement Boston Scientific's condensed consolidated financial statements presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income, non-GAAP net income per share, and regional and divisional reve...

Discloses in Medical Technology

AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and...

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles

JMR-132 could provide a new therapeutic approach for the treatment of early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract...

terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUBEC CITY, Canada, April 16, 2007 terna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global, pure play biopharmaceutical company foc...

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting

Ozarelix improved LUTS symptoms and urine flow over 28-week period QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Spectrum Pharmaceuticals presented an abstrac...

Discloses in Biological Technology

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today disclosed preliminary results for the Company's European multi-center Phase 2 trial in non-small cell lung cancer (NSC...

Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement

WARSAW, Ind., Oct. 4 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA ), an independent provider of products to the global orthopedic device industry and other medical markets, announced today that the Audit Committee of its Board of Directors has initiated an independent review of ...

Genmab Discloses Target and Development Plans for HuMax-Inflam

Summary: Genmab Reveals That HuMax-Inflam Target is IL-8 and Future Development Will be in Cancer and Inflammation COPENHAGEN, September 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today its fully human HuMax-Inflam(TM) antibody is directed to IL-8 (interleukin-8...

NxStage Reports Second Quarter 2009 Financial Results

...Kristen K. Sheppard, Esq. VP, Investor Relations 978-332-5923 ksheppard@nxstage.com Non-GAAP Financial Measure The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is...

NxStage Reports First Quarter 2009 Financial Results

... Contact: Kristen K. Sheppard, Esq. VP, Investor Relations ksheppard@nxstage.com Non-GAAP Financial Measure The Company discloses a non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in ...

Patent for Making Combination Chemotherapy Work Better

...AN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also call...

Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge

...ent Use of Non-GAAP Financial Measures To supplement Boston Scientific's financial information presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income and non-GAAP net income per diluted share. These non-GAAP measur...

Boston Scientific Announces Results for Third Quarter Ended September 30, 2008

... of Non-GAAP Financial Measures To supplement Boston Scientific's condensed consolidated financial statements presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income, non-GAAP net income per diluted share, and regional and divisio...

PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application

...d other forms of legal relief. Subsequent to the filing of its complaint, PSKW learned that McKesson had filed a patent application that incorporates, discloses and claims ownership over some of the trade secrets and other confidential and proprietary information relating to co-pay offset programs and methods ...

Boston Scientific Announces Results for First Quarter Ended March 31, 2008

...of Non-GAAP Financial Measures To supplement Boston Scientific's condensed consolidated financial statements presented on a GAAP basis; the Company discloses certain non- GAAP measures that exclude certain amounts, including non-GAAP net income, non-GAAP net income per diluted share, and regional and divi...

Discloses in Biological Dictionary

Shuttle vector

.... Baby A's. Shady. Grove. Chuy's. Free Express Shuttle . Ster. zing S. t. Sunset. View. Toomy Rd. Virginia A. ve. Town Lake Park ... The invention discloses a Lac shuttle vector , comprising at least (a) a region ... Its use in Shuttle Vector Construction, 1989, Plasmid 22: 193-202. ... Provided ...